Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results

Antonio Santoro, Giuseppe Minniti, Andrea Ruggeri, Vincenzo Esposito, Marie Lise Jaffrain-Rea, Roberto Delfini

Research output: Contribution to journalArticle

Abstract

Background: Transsphenoidal surgery is safe and effective in patients with secreting pituitary adenomas; however, variable outcomes have been reported according to the different criteria used to define the biochemical remission of hormone hypersecretion. We report the long-term endocrinologic follow-up results of a large cohort of patients who underwent TSS for secreting pituitary adenomas according to the most recent stringent criteria of cure. Methods: Two hundred ten consecutive patients were operated on by TSS between 1995 and 2004 for a secreting pituitary adenoma (65 PRL-, 109 GH-, and 36 ACTH-secreting adenomas) and were considered for the study. Results: The overall remission rate was 65% for the whole series, being 64%, 61%, and 75% for PRL-, GH-, and ACTH-secreting adenomas, respectively. Eighty-six percent of microadenomas and 53% of macroadenomas were cured by surgery. Remission rates were significantly higher in GH- and ACTH-secreting pituitary macroadenomas than in macroprolactinomas. At a median follow-up of 56 months, tumor recurrence was 0%, 11%, and 14% for GH-, ACTH-, and PRL-secreting tumors. Tumor size, cavernous sinus invasion, and high hormone levels were negatively correlated to the outcome. Conclusion: Transsphenoidal surgery remains an effective treatment for secreting pituitary tumors according to the most recent criteria of cure. Patients with PRL- or ACTH-secreting adenomas may recur after apparently successful surgery, thereby justifying long-term careful endocrinologic follow-up.

Original languageEnglish
Pages (from-to)513-518
Number of pages6
JournalSurgical Neurology
Volume68
Issue number5
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Pituitary Neoplasms
Adrenocorticotropic Hormone
Recurrence
Adenoma
Prolactinoma
Hormones
Neoplasms
Cavernous Sinus

Keywords

  • Acromegaly
  • Cushing disease
  • Pituitary adenoma
  • Prolactinoma
  • Transsphenoidal surgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy : long-term endocrinologic follow-up results. / Santoro, Antonio; Minniti, Giuseppe; Ruggeri, Andrea; Esposito, Vincenzo; Jaffrain-Rea, Marie Lise; Delfini, Roberto.

In: Surgical Neurology, Vol. 68, No. 5, 11.2007, p. 513-518.

Research output: Contribution to journalArticle

Santoro, Antonio ; Minniti, Giuseppe ; Ruggeri, Andrea ; Esposito, Vincenzo ; Jaffrain-Rea, Marie Lise ; Delfini, Roberto. / Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy : long-term endocrinologic follow-up results. In: Surgical Neurology. 2007 ; Vol. 68, No. 5. pp. 513-518.
@article{b1d81c55f0cc4e6fae061bb4b5cb1e2a,
title = "Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results",
abstract = "Background: Transsphenoidal surgery is safe and effective in patients with secreting pituitary adenomas; however, variable outcomes have been reported according to the different criteria used to define the biochemical remission of hormone hypersecretion. We report the long-term endocrinologic follow-up results of a large cohort of patients who underwent TSS for secreting pituitary adenomas according to the most recent stringent criteria of cure. Methods: Two hundred ten consecutive patients were operated on by TSS between 1995 and 2004 for a secreting pituitary adenoma (65 PRL-, 109 GH-, and 36 ACTH-secreting adenomas) and were considered for the study. Results: The overall remission rate was 65{\%} for the whole series, being 64{\%}, 61{\%}, and 75{\%} for PRL-, GH-, and ACTH-secreting adenomas, respectively. Eighty-six percent of microadenomas and 53{\%} of macroadenomas were cured by surgery. Remission rates were significantly higher in GH- and ACTH-secreting pituitary macroadenomas than in macroprolactinomas. At a median follow-up of 56 months, tumor recurrence was 0{\%}, 11{\%}, and 14{\%} for GH-, ACTH-, and PRL-secreting tumors. Tumor size, cavernous sinus invasion, and high hormone levels were negatively correlated to the outcome. Conclusion: Transsphenoidal surgery remains an effective treatment for secreting pituitary tumors according to the most recent criteria of cure. Patients with PRL- or ACTH-secreting adenomas may recur after apparently successful surgery, thereby justifying long-term careful endocrinologic follow-up.",
keywords = "Acromegaly, Cushing disease, Pituitary adenoma, Prolactinoma, Transsphenoidal surgery",
author = "Antonio Santoro and Giuseppe Minniti and Andrea Ruggeri and Vincenzo Esposito and Jaffrain-Rea, {Marie Lise} and Roberto Delfini",
year = "2007",
month = "11",
doi = "10.1016/j.surneu.2007.05.057",
language = "English",
volume = "68",
pages = "513--518",
journal = "Surgical Neurology",
issn = "0090-3019",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy

T2 - long-term endocrinologic follow-up results

AU - Santoro, Antonio

AU - Minniti, Giuseppe

AU - Ruggeri, Andrea

AU - Esposito, Vincenzo

AU - Jaffrain-Rea, Marie Lise

AU - Delfini, Roberto

PY - 2007/11

Y1 - 2007/11

N2 - Background: Transsphenoidal surgery is safe and effective in patients with secreting pituitary adenomas; however, variable outcomes have been reported according to the different criteria used to define the biochemical remission of hormone hypersecretion. We report the long-term endocrinologic follow-up results of a large cohort of patients who underwent TSS for secreting pituitary adenomas according to the most recent stringent criteria of cure. Methods: Two hundred ten consecutive patients were operated on by TSS between 1995 and 2004 for a secreting pituitary adenoma (65 PRL-, 109 GH-, and 36 ACTH-secreting adenomas) and were considered for the study. Results: The overall remission rate was 65% for the whole series, being 64%, 61%, and 75% for PRL-, GH-, and ACTH-secreting adenomas, respectively. Eighty-six percent of microadenomas and 53% of macroadenomas were cured by surgery. Remission rates were significantly higher in GH- and ACTH-secreting pituitary macroadenomas than in macroprolactinomas. At a median follow-up of 56 months, tumor recurrence was 0%, 11%, and 14% for GH-, ACTH-, and PRL-secreting tumors. Tumor size, cavernous sinus invasion, and high hormone levels were negatively correlated to the outcome. Conclusion: Transsphenoidal surgery remains an effective treatment for secreting pituitary tumors according to the most recent criteria of cure. Patients with PRL- or ACTH-secreting adenomas may recur after apparently successful surgery, thereby justifying long-term careful endocrinologic follow-up.

AB - Background: Transsphenoidal surgery is safe and effective in patients with secreting pituitary adenomas; however, variable outcomes have been reported according to the different criteria used to define the biochemical remission of hormone hypersecretion. We report the long-term endocrinologic follow-up results of a large cohort of patients who underwent TSS for secreting pituitary adenomas according to the most recent stringent criteria of cure. Methods: Two hundred ten consecutive patients were operated on by TSS between 1995 and 2004 for a secreting pituitary adenoma (65 PRL-, 109 GH-, and 36 ACTH-secreting adenomas) and were considered for the study. Results: The overall remission rate was 65% for the whole series, being 64%, 61%, and 75% for PRL-, GH-, and ACTH-secreting adenomas, respectively. Eighty-six percent of microadenomas and 53% of macroadenomas were cured by surgery. Remission rates were significantly higher in GH- and ACTH-secreting pituitary macroadenomas than in macroprolactinomas. At a median follow-up of 56 months, tumor recurrence was 0%, 11%, and 14% for GH-, ACTH-, and PRL-secreting tumors. Tumor size, cavernous sinus invasion, and high hormone levels were negatively correlated to the outcome. Conclusion: Transsphenoidal surgery remains an effective treatment for secreting pituitary tumors according to the most recent criteria of cure. Patients with PRL- or ACTH-secreting adenomas may recur after apparently successful surgery, thereby justifying long-term careful endocrinologic follow-up.

KW - Acromegaly

KW - Cushing disease

KW - Pituitary adenoma

KW - Prolactinoma

KW - Transsphenoidal surgery

UR - http://www.scopus.com/inward/record.url?scp=35348998073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348998073&partnerID=8YFLogxK

U2 - 10.1016/j.surneu.2007.05.057

DO - 10.1016/j.surneu.2007.05.057

M3 - Article

C2 - 17961741

AN - SCOPUS:35348998073

VL - 68

SP - 513

EP - 518

JO - Surgical Neurology

JF - Surgical Neurology

SN - 0090-3019

IS - 5

ER -